PO.IM01.11 · 免疫学

肌红蛋白表达增强T细胞代谢和抗肿瘤效应功能

Myoglobin expression boosts T-cell metabolism and antitumor effector function

海报缩略图:肌红蛋白表达增强T细胞代谢和抗肿瘤效应功能
编号 2806 展板 11 时间 4/20 02:00–05:00 区域 Section 7 主讲 Julia Werner
分会场 Immune Checkpoints
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Julia Werner1, Haifeng Xu1, Georgios Theodorakis1, Ichiro Katahira1, Mitrajit Ghosh1, Michal Gorzkiewicz1, Luisa de Sousa Santos1, Ann Kathrin Bergmann1, Max Anstötz1, Anne Busch1, Diran Herebian1, Sascha Dietrich1, Carsten Berndt1, Ertan Mayatepek 1, Aleksandra Pandyra2, Dirk Brenner3, Philipp Lang1

1University Hospital of Düsseldorf, Düsseldorf, Germany,2University Hospital Bonn, Bonn, Germany,3University of Luxembourg, Luxembourg, Luxembourg

摘要 Abstract

中文摘要
肿瘤微环境常处于缺氧状态,并以营养资源匮乏为特征,包括葡萄糖供应有限。由于效应T细胞具有高能量需求,肿瘤代谢可导致T细胞功能障碍和耗竭。在本研究中,我们利用RT-PCR、组织学和流式细胞术评估了荷瘤C57BL/6J小鼠脾脏和肿瘤组织中的缺氧情况。接下来,从C57BL/6J或P14+小鼠分离的CD8+ T细胞用Thy1.1(对照)或Thy1.1-肌红蛋白(Mb)包装逆转录病毒转导,并通过RT-PCR和Western blot确认Mb表达。使用流式细胞术、TEM、FIB-SEM、Seahorse检测、代谢组学和基于发光的方法分析这些细胞的代谢。此外,通过流式细胞术在体外测量效应功能。将P14+ CD45.1+ CD8+ Mb转导T细胞和对照T细胞转移至B16F10-gp33或MC38-ova荷瘤小鼠体内,并通过流式细胞术和组织学进行分析。最后,B16F10-gp33荷瘤小鼠接受了额外的抗PD-1检查点抑制剂治疗。在此,我们证明T细胞中表达携氧蛋白肌红蛋白能够增强其线粒体和糖酵解代谢功能。在肌红蛋白存在的情况下,代谢物和TCA循环中间产物显著增加,并与ATP水平升高相关联。表达肌红蛋白的T细胞在活化后及浸润肿瘤微环境期间表现出降低的HIF-1alpha表达。相应地,肌红蛋白表达在体外增强了效应T细胞对肿瘤细胞的功能,并伴随超氧化物水平降低。过继转移至荷瘤小鼠后,肌红蛋白表达促进了更强的肿瘤微环境浸润。尽管表达肌红蛋白的T细胞显示出效应细胞因子表达增加,但PD-1仍可检测到并可被抗PD-1单克隆抗体靶向,当后者与肌红蛋白表达T细胞的转移联合使用时,在延缓肿瘤生长方面达到了最大疗效。综上所述,我们证明T细胞中表达肌红蛋白可增强其代谢、肿瘤组织浸润及对癌细胞的效应功能。
查看英文原文 English abstract
The tumor microenvironment is frequently hypoxic and characterized by a scarcity of nutritional resources, including limited glucose availability. As effector T cells have high energy demands, tumor metabolism can contribute to T-cell dysfunction and exhaustion. In this study, we assessed hypoxia in spleen and tumor tissue from tumor-bearing C57BL/6J mice using RT-PCR, histology, and flow cytometry. Next, CD8⁺ T cells isolated from C57BL/6J or P14⁺ mice were transduced with a Thy1.1 (control) or Thy1.1-myoglobin (Mb) packaging retrovirus, and Mb expression was confirmed by RT-PCR and Western blot. The metabolism of these cells was analysed using flow cytometry, TEM, FIB-SEM, Seahorse assays, metabolomics, and luminescence-based approaches. Furthermore, effector function was measured in vitro by flow cytometry. P14⁺ CD45.1⁺ CD8⁺ Mb-transduced and control T cells were transferred into B16F10-gp33 or MC38-ova tumor-bearing mice and analysed by flow cytometry and histology. Finally, B16F10-gp33 tumor-bearing mice received additional treatment with an anti-PD-1 checkpoint inhibitor. Here, we demonstrate that expression of the oxygen-binding protein myoglobin in T cells can enhance their mitochondrial and glycolytic metabolic functions. Metabolites and TCA cycle intermediates were markedly increased in the presence of myoglobin and were associated with elevated ATP levels. Myoglobin-expressing T cells exhibited reduced HIF-1alpha expression after activation and during infiltration into the tumor microenvironment. Accordingly, myoglobin expression increased effector T-cell function against tumor cells in vitro, accompanied by reduced superoxide levels. Following adoptive transfer into tumor-bearing mice, myoglobin expression promoted greater infiltration into the tumor microenvironment. Although myoglobin-expressing T cells showed increased effector cytokine expression, PD-1 remained detectable and targetable by anti-PD-1 monoclonal antibodies, which-when combined with transfer of myoglobin-expressing T cells-achieved maximal efficacy in delaying tumor growth. Taken together, we show that expression of myoglobin in T cells enhances their metabolism, infiltration into tumor tissue, and effector function against cancer cells.
利益披露 Disclosure
J. Werner, Abalos Therapeutics GmbH Employment. H. Xu, Abalos Therapeutics GmbH Employment. G. Theodorakis, Abalos Therapeutics GmbH Employment. I. Katahira, None.. M. Ghosh, None.. M. Gorzkiewicz, None. L. de Sousa Santos, Abalos Therapeutics GmbH ). A. Bergmann, None.. M. Anstötz, None.. A. Busch, None.. D. Herebian, None.. S. Dietrich, None.. C. Berndt, None.. E. Mayatepek , None.. A. Pandyra, None.. D. Brenner, None. P. Lang, Abalos Therapeutics GmbH Scientific Founder.

← 返回 AACR 2026 检索